Combination therapy improves outcomes for hormone-sensitive invasive lobular breast cancer

consultqd.clevelandclinic.org

Combination therapy improves outcomes for hormone-sensitive breast cancer patients with invasive lobular carcinoma. Ribociclib and fulvestrant showed better progression-free and overall survival than fulvestrant alone, confirming it as the best approach for these patients. Despite improvements, lobular patients still had slightly shorter survival than the overall study population, suggesting different biology requiring further investigation.


With a significance score of 5.1, this news ranks in the top 1.4% of today's 30565 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Combination therapy improves outcomes for hormone-sensitive invasive lobular breast cancer | News Minimalist